Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628846 | 0.86 | ACLY (0.58) | ACLYHCRTR1HCRTR2HSD11B1 | |
| SCHEMBL4610371 | 0.85 | ACLY (0.62) | ACLY | |
| SCHEMBL4611418 | 0.85 | ACLY (0.62) | ACLY | |
| SCHEMBL5578249 | 0.83 | ACLY (0.55) | ACLYHCRTR1HCRTR2HSD11B1 | |
| SCHEMBL4610646 | 0.81 | ACLY (0.67) | ACLY | |
| SCHEMBL4612655 | 0.81 | ACLY (0.67) | ACLY | |
| SCHEMBL4610642 | 0.81 | ACLY (0.67) | ACLY | |
| SCHEMBL3901904 | 0.81 | ITGB1 (0.59) | CASP3HCRTR1HCRTR2 | |
| SCHEMBL3901901 | 0.81 | ITGB1 (0.59) | CASP3HCRTR1HCRTR2 | |
| SCHEMBL31645166 | 0.81 | HCRTR1 (0.53) | CASP3HCRTR1HCRTR2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981845-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
| WO-2007092558-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | ACLY 2581/4885CASP3 879/4885HCRTR1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.